Main skin diseases of the elderly

Lisievici, Cristina; Lupu, Mihai; Ion, Alexandra Victoria; Voiculescu, Vlad Mihai; Giurcăneanu, Călin

doi:10.26416/med.128.1.2018.1533

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BCC's incidence is increasing by 10% every year among white people living in geographical areas with high sun exposure, like Australia [5–7]. Unlike SCC, which may be lethal, BCC is only aggressive through its local extension and has high recurrence rate if the surgical treatment is not properly carried out [8].…”

Section: Introductionmentioning

confidence: 99%

Mediators of Inflammation in Topical Therapy of Skin Cancers

Voiculescu

Lisievici

Lupu

et al. 2019

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

Taking into consideration that the immune system plays a very important role in the development of melanoma and non-melanoma skin cancers, which have a high prevalence in immunosuppressed patients and after prolonged ultraviolet radiation, the interest in developing novel therapies, in particular targeting the inflammation in cancer, has increased in the past years. The latest data suggest that therapies such as imiquimod (IMQ), ingenol mebutate (IM), 5-fluorouracil (5-FU), retinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been used with success in the topical treatment of some cancers. Herein, we review the topical treatment targeting the inflammation in skin cancer and the mechanisms involved in these processes. Currently, various associations have shown a superior success rate than monotherapy, such as systemic acitretin and topical IMQ, topical 5-FU with tretinoin cream, or IMQ with checkpoint inhibitor cytotoxic T lymphocyte antigen 4. Novel therapies targeting Toll-like receptor-7 (TLR-7) with higher selectivity than IMQ are also of great interest.

show abstract

Section: Introductionmentioning

confidence: 99%